bcl-2 inhibitor loxo-338
Generic: Bcl-2 Inhibitor LOXO-338
bcl-2 inhibitor loxo-338: 2 clinical trials tracked.
bcl-2 inhibitor loxo-338 evidence translation
What we can confirm
2 tracked trials
No verified listed company relationship
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about bcl-2 inhibitor loxo-338, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence4 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (2)
Master Rollover Protocol for Continued Safety Assessment of Study Drug
Expanded Access3 sites · United StatesEli Lilly and Company
A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients With Advanced Hematologic Malignancies
Primary endpoint: Part 1 - To determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of oral LOXO-338
InterventionalRandomizedopen27 enrolledStarted 2021-09Completion 2026-0323 sites · France, Italy, Poland, United StatesEli Lilly and Company